Asthma & Immunology annual meeting (AAAAI 2025). LP-003 demonstrated superior improvement compared to Omalizumab in mean change of UAS7 (urticaria activity score 7) from baseline and percentage ...
Co., Ltd. (referred to as "Longbio"), a leading biotech company dedicated to developing innovative biologic treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback